Literature DB >> 10996581

Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests.

P D Stein1, R D Hull, G E Raskob.   

Abstract

PURPOSE: Patients who have nonmassive acute pulmonary embolism and a high risk of bleeding or contraindication to anticoagulants, such recent surgery or gastrointestinal bleeding, present a clinical dilemma. We sought to estimate whether such patients could be safely left untreated if serial compression ultrasound or serial impedance plethysmography were negative and cardiorespiratory reserve was adequate. SUBJECTS AND METHODS: The frequency of recurrent pulmonary embolism among patients with nonmassive acute pulmonary embolism and negative serial noninvasive leg tests who were not treated was estimated from two prospective studies of the noninvasive management of patients with suspected pulmonary embolism. One of the studies used serial impedance plethysmography of the lower extremities; the other used serial compression ultrasound. The prevalence of pulmonary embolism in patients with nondiagnostic ventilation/perfusion lung scans was determined from the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED).
RESULTS: The estimated frequency of fatal recurrent pulmonary embolism was 1% [95% confidence interval (CI), 0% to 5%) among untreated patients with nonmassive pulmonary embolism who had negative serial impedance plethysmograms and 0% (95% CI, 0% to 4%) among those with negative serial compression ultrasonograms. The frequency of nonfatal recurrent pulmonary embolism among untreated patients was 3%, regardless of whether they had negative serial impedance plethysmograms or negative serial compression ultrasonograms. These results were comparable with the frequency of recurrent pulmonary embolism among patients treated with anticoagulants or with inferior vena cava filters.
CONCLUSION: Withholding treatment of nonmassive acute pulmonary embolism, if serial impedance plethysmograms or serial venous ultrasonograms are negative and cardiopulmonary reserve is adequate, is a possible strategy for the management of patients with a high risk of bleeding or other contraindication to anticoagulants. This strategy may be associated with fewer adverse events than treatment with anticoagulants or an inferior vena cava filter. Prospective trials comparing alternative treatments are needed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996581     DOI: 10.1016/s0002-9343(00)00508-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 2.  The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism.

Authors:  Halil Doğan; Albert de Roos; Jacob Geleijins; Menno V Huisman; Lucia J M Kroft
Journal:  Diagn Interv Radiol       Date:  2015 Jul-Aug       Impact factor: 2.630

3.  Detection of acute pulmonary embolism: feasibility of diagnostic accuracy of MRI using a stepwise protocol.

Authors:  Waldemar Hosch; Martin Schlieter; Sebastian Ley; Tobias Heye; Hans-Ulrich Kauczor; Martin Libicher
Journal:  Emerg Radiol       Date:  2013-11-27

4.  Saddle versus non-saddle pulmonary embolism: differences in the clinical, echocardiographic, and outcome characteristics.

Authors:  Wanis H Ibrahim; Shaikha D Al-Shokri; Musa S Hussein; Antoun Kamel; Lana M Abu Afifeh; Gowri Karuppasamy; Jessiya V Parambil; Farras M Elasad; Mohamed S Abdelghani; Ahmed Abdellah; Mohammed E Faris
Journal:  Libyan J Med       Date:  2022-12       Impact factor: 1.657

5.  Survival after cardiac arrest secondary to high-risk pulmonary embolism without reperfusion therapies: A case report.

Authors:  Cai-Yun Xu; Jia-Fu Song; Li-Hong Yao; Hui-Ling Xu; Ke-Xi Liu
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.